This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Accelrys ELN Advances Innovation Lifecycle Management With Enhanced Biology Capabilities From Screening To Preclinical Development

SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced that the latest release of the company's enterprise electronic laboratory notebook (ELN), Symyx Notebook by Accelrys, offers a new multidimensional scientific spreadsheet for use in planning, executing and tracking a wide range of biological experiments. In addition, powerful new project tracking and optimization software provides a more complete biology solution, from efficient study orchestration to study execution in the lab. Together, the new ELN capabilities accelerate scientific innovation lifecycle management across a range of chemical and biological experimentation, helping bridge the productivity gap from innovation through commercialization.

To view the multimedia assets associated with this release, please click  

By significantly improving bench scientists' ability to capture, mine and reuse experiment and study information from within the ELN, the new scientific spreadsheet improves data access, enhances knowledge management and reduces laboratory cycle times. The new project tracking and optimization capabilities improve collaboration and cascade management for project teams while enhancing study visibility and capacity management for study directors.

"The new spreadsheet and unique project tracking capabilities accelerate end-to-end innovation productivity for discovery and development scientists, especially those working in preclinical development," said Accelrys' Senior Vice President and Chief Technology Officer, Dr. Matt Hahn. "We have seen significant cycle time reductions resulting from improved information flow across the research cascade and more streamlined coordination of tasks and teams in this collaborative environment."

Integration of the new notebook capabilities with the scientifically aware Accelrys Enterprise Platform supports the combined management of information, tasks and collaboration from early-phase screening and assay development through downstream drug metabolism and pharmacokinetics, ADMET, bioanalytical and in vivo pharmacology. The Platform's extensive scientific Component Collections, built on Accelrys' deep domain expertise in chemistry, biology, materials science, informatics and predictive science, rapidly and cost-effectively deliver advanced imaging, modeling and analytics capabilities supporting scientific workflows from research to development.

Today's drug discovery process requires coordination among multiple teams within the enterprise and, increasingly, across geographical and organizational boundaries. In this challenging R&D environment, the new ELN capabilities from Accelrys improve access to information, foster better collaboration and speed laboratory cycle times by providing:
  • A multidimensional scientific spreadsheet with flexible templates that enable teams to capture, analyze, report and share data from plate-based screening experiments to behavioral studies
  • Enhanced data management, storage and access, enabling rapid data aggregation, searching and reporting for improved insights and faster decisions
  • An integrated system for tracking and optimizing project, study and laboratory workflows. The system supports cascades of services with progression rules for transitioning activities from one stage to the next. Interactive reports record materials and resource usage across the cascades, highlighting bottlenecks and empowering managers to fine-tune resource utilization and allocation

For more information on informatics-driven study orchestration and execution in preclinical development, visit You can also register for the complimentary webinar, " Informatics-Driven Project Execution for In Vivo Pharmacology," scheduled for 8 a.m. PDT, Wednesday, Sept. 12.

About Accelrys, Inc.

Accelrys (NASDAQ:ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs